The purpose of this study is to determine if a pessary, a silicone device placed within the vagina to support the cervix, could be a good way to help pregnant women who are at risk for preterm delivery. The pessary that is used in this study, called the Arabin pessary, has not been approved by the United States Food and Drug Administration (FDA) for the prevention of preterm delivery. It is an investigational device, which means it is still being studied to find out whether or not it is safe and effective in patients with a short cervix who are at risk for preterm delivery.
The primary purposes of this study are to:
?Provide access to cord blood units for recipients whose best choice for a cord blood unit(s) do not meet all FDA standards, but do meet standards set by the NMDP on this study.
?Assess how well and how quickly blood counts return to normal after transplant in recipients on this study.
This study is for participants who have been diagnosed with cancers of the blood who do not have a related perfect tissue ?match? for BMT. This research is being done to find out if a bone marrow transplant (BMT) from a relative who is not a perfect tissue match is safe and effective in people with cancer. The primary goal of this study is to use chemotherapy and/or radiation therapy to completely get rid of a person?s existing bone marrow, give them new bone marrow from a relative who is not a perfect tissue match, and then give them two doses of additional chemotherapy shortly after receiving the new bone marrow. Participants can expect to be in this study for up to 2 years.
AZD5363 is a new anti-cancer treatment being developed by AstraZeneca that has not yet been approved for use. This study is part of a research project for collecting information about the safety and effectiveness of this treatment for the first time. The main purpose of the study is to establish a safe dose of the drug by gathering information on how well it is tolerated, any potential side effects it may cause and collecting data about how your cancer responds to the drug. The study will also measure the levels of AZD5363 in the blood and the action of AZD5363 in the body over a period of time. It will also indicate whether the drug has an effect on the type of cancer that the subjects have.
Lung cancer is the leading cause of cancer death with a higher mortality rate among African Americans. For patients that have stage I or II non-small cell cancer, surgery is the only curative treatment. In a previous study we conducted, we found that African Americans were less likely to have surgery than other groups. The purpose of this study is to find out what patients understand about their medical condition, what can be done to get the very best lung cancer surgery treatment, and how we can close the treatment gap.
This study will use focus groups, individual interviews and secondary data analysis to gather information to gain better understanding of best source, format and preference for a weight loss intervention and receiving health information that integrate genetics, socio-environmental, and behavioral factors into a promising multi-level community based intervention for obesity and obesity promoting behaviors in African American (AA) women.
This study is for patients that have been diagnosed with Multiple Myeloma and have received at least two previous treatments for the cancer and the cancer has either remained stable or worsened during or after your last treatment. The investigational drug in this study is ibrutinib. The purpose of this study is to determine the Phase 2b doses of ibrutinib and pomalidomide to be used with dexmethasone in combination. Participants can expect to be in this study for approximately 2 years.
This study is for patients that have been diagnosed with platinum-sensitive ovarian cancer.The investigational drug in this study is Farletuzumab. The main purpose of this study is to find out if carboplatin plus paclitaxel or carboplatin plus Pegylated Liposomal Doxorubicin (PLD), chemotherapies (anticancer drugs) that are used to treat ovarian cancer, work better alone or when given with an farletuzumab.
The estimated total duration of this study will be approximately 46 months (1 month screening, 15 months treatment, and 30 months follow-up). The actual total duration will vary depending on subject response to drug and disease progression
This study will assess the efficacy and safety of pembrolizumab (MK-3475) in women with advanced ovarian cancer who have demonstrated recurrent disease following the front line platinum-based treatment and debulking surgery and received up to 5 lines of treatment for recurrent ovarian cancer (ROC) per local standard of care. Participants will receive pembrolizumab every 3 weeks (Q3W) for up to 2 years.